Latest News and Press Releases

Corporate and Regulatory Highlights U.S. Commercial Launch of AZSTARYS™ Initiated on July 21, 2021Serdexmethylphenidate (SDX) Classified as a Schedule IV Controlled Substance by the DEAAnnounced...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...

CELEBRATION, Fla., July 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...

CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...

CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...

CELEBRATION, Fla., June 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced...

CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...

SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™ CELEBRATION, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- KemPharm,...

Corporate and Regulatory Highlights AZSTARYSTM NDA approved by the FDA on March 2, 2021Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of...

KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA CELEBRATION, Fla., May 07, 2021 ...